about
Routine versus selective antifungal administration for control of fungal infections in patients with cancerTherapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspectiveDrug-induced acute myocardial infarction: identifying 'prime suspects' from electronic healthcare records-based surveillance systemFungal infection-related mortality versus total mortality as an outcome in trials of antifungal agents.Routine versus selective antifungal administration for control of fungal infections in patients with cancer.Primary cutaneous blastomycosis as a cause of acute respiratory distress syndrom: case report and literature review.Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies.Adverse drug event monitoring at the Food and Drug Administration.Pharmacotherapy of Candida bloodstream infections: new treatment options, new era.Management of histoplasmosis.Clinical safety and tolerability issues in use of triazole derivatives in management of fungal infections.Itraconazole--perspectives for the management of invasive aspergillosis.Management of Onychomycosis in Canada in 2014.Fungal infections: their diagnosis and treatment in transplant recipients.Current use of anti-infectives in dermatology.Association of systolic blood pressure drop with intravenous administration of itraconazole in children with hemato-oncologic diseaseInvasive fungal infections in acute leukemia.Antifungal prophylaxis following reduced-intensity stem cell transplantation.Current options in antifungal pharmacotherapy.Defining targets for investigating the pharmacogenomics of adverse drug reactions to antifungal agents.Management of fungal infections following allogeneic stem cell transplantation.Heart failure induced by itraconazole.Tissue penetration of antifungal agents.Safety of triazole antifungal drugs in patients with cancer.Antifungal prophylaxis and therapy in patients with hematological malignancies and hematopoietic stem cell transplant recipients.Current concepts in antifungal pharmacology.Itraconazole: an update on pharmacology and clinical use for treatment of invasive and allergic fungal infections.Antifungal prophylaxis following heart transplantation: systematic review.Fungal infections of the skin and nail: new treatment options.Cardiac arrest provoked by itraconazole and amiodarone interaction: a case report.Antifungal-Associated Drug-Induced Cardiac Disease.Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.From the Cover: High-Throughput Imaging of Cardiac Microtissues for the Assessment of Cardiac Contraction during Drug Discovery.Clinical Manifestations and Treatment of Blastomycosis.Cutaneous Phaeohyphomycosis Caused by Exophiala attenuata in a Domestic Cat.Reversible dilated cardiomyopathy associated with amphotericin B therapy.Overinfection by Paracoccidioides brasiliensis in Gouty Crystal Arthritis.Nanosuspension formulation of itraconazole eliminates the negative inotropic effect of SPORANOX in dogs.A pilot study of targeted itraconazole prophylaxis in patients with graft-versus-host disease at high risk of invasive mould infections following allogeneic stem cell transplantation.Cardiovascular function in nonclinical drug safety assessment: current issues and opportunities.
P2860
Q24193817-8A502FF3-0692-41DB-928A-EC4206DF48D6Q27009221-1FC73431-0B93-4485-8BF6-A1DFDEE69D00Q28535919-3C70D26C-6DF5-4B39-A319-1459B3B3DED9Q33253851-B3C84BB2-10AD-4A9F-A19C-80853EC8C5EDQ33909375-89E15753-4DDB-4E5C-AAC9-0698D34B36CAQ34074183-9BE569AB-4D62-4C81-ABB0-5B6F38E79716Q34301513-61CF135D-1ECB-4BA7-9D68-5F29D7EABAA7Q34740872-001A9562-87D7-4CD9-A65A-7621E32DB575Q34768471-2F8D3442-DC29-4E6B-B633-063D4AB7DA7FQ34768480-CAFE25C7-077C-42B8-AFD7-D7D394EE70C7Q35026481-E648FBC2-9180-4EC5-B38E-7CC00DF84F57Q35105394-57E48D02-E58B-47B3-B60D-D3D39FA697EBQ35578703-59A6C0D7-BC6A-4BFC-B6BF-6FC4E03A46AAQ36206568-1326992A-CCBE-4C84-91DE-7050A8F8B1FFQ36233506-969A56E1-103E-4D6B-A94A-4291205F07AAQ36394498-03C366ED-65A4-4ECD-AE64-22C411A3DD49Q36612597-B53E0BBD-8D1F-45C8-A7A3-B4ED829509A3Q36658236-C4231BDB-6EA0-4765-BD0D-05F9336DFBC8Q37151326-CC0C507A-CE97-415C-84D4-FCD6935C75A9Q37157893-C5DBA250-E060-4E5B-8409-A4C4AE929430Q37202860-3F3A82EC-07E0-48D6-AF2E-AE8F5221FABAQ37222505-65CA26E4-8F53-4B2F-AB25-A662A7BC32BAQ37544911-80F20DE6-F535-4302-90FE-95CB6F9E0CE1Q37662650-BC99AFAB-5E12-4319-877A-381785E4B440Q37816399-2E77E73B-3C6F-4D43-915A-CDCDBD2BCC24Q37908856-9F2EB29B-1E85-4B8B-86D0-91D85D04AEF1Q38103889-1736D50F-5DD5-4C2F-975E-6FA069F07CFBQ38192768-F366D753-6590-4664-9FAB-4537324011E3Q38252946-56E1CEB8-701F-485B-B6A4-A665B0864D7BQ38261938-3989B6A1-2578-43D0-8118-F7968D0A7587Q38633109-261D8777-1D13-4FD5-8314-2D3A215D0075Q38681635-24BF28C1-47C6-4FFD-804C-6272BD7EFF91Q39030459-2B457393-D697-47F2-83F9-89865B711328Q40098273-E863DED3-FEC6-43A7-B5E7-F2802C6B4C13Q40822425-B4480EE0-D538-4EAB-88E2-265AECBF7327Q41610197-D193FAB3-E9AC-4BBE-8D19-7C78B5159FC1Q42365123-22218B74-3FFB-4290-A025-36A76441EE3FQ42874862-D67EDBA4-9294-4616-8396-AFC4F4AFBD14Q44973658-3B54F1C6-31F3-4CA4-A233-48CC76EB9838Q45022373-3743AED7-27CE-4B90-AEC5-360013CCBB2D
P2860
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Congestive heart failure associated with itraconazole.
@en
Congestive heart failure associated with itraconazole.
@nl
type
label
Congestive heart failure associated with itraconazole.
@en
Congestive heart failure associated with itraconazole.
@nl
prefLabel
Congestive heart failure associated with itraconazole.
@en
Congestive heart failure associated with itraconazole.
@nl
P2093
P1433
P1476
Congestive heart failure associated with itraconazole.
@en
P2093
P304
P356
10.1016/S0140-6736(00)04891-1
P407
P577
2001-06-01T00:00:00Z